Phathom Pharmaceuticals' Robert Breedlove to Resign as Finance VP

Phathom Pharmaceuticals' VP of Finance, Robert Breedlove, will resign on December 4, 2026, according to an SEC filing. The company stated his departure is not due to any disagreement with its operations or policies. No replacement has been announced.

Original reporting
Published Nov 18, 2026, 9:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 18, 2026, 9:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Phathom Pharmaceuticals' Robert Breedlove to Resign as Finance VP — source image
Decision brief

The 30-second read

$PHATNeutralLow
01

Why it matters

This is a governance and internal-controls continuity item. Without a named replacement or stated operational dispute, the market impact is likely limited unless follow-on filings disclose interim accounting leadership changes or material control issues.

02

Market read

The disclosure may prompt short-term scrutiny of finance/accounting continuity, but it does not provide operational or financial performance information.

03

What to watch

Traders may be over-weighting the resignation without knowing whether the company already has interim finance coverage or a previously announced succession plan.

Relevance 5/10Novelty 6/10Timing: immediate after-hours/next-session positioning ahead of the Dec 4 effective date

Background

The company filed an 8-K on Nov. 18, 2026 announcing the resignation of its VP of Finance and principal accounting officer, effective Dec. 4, 2026.

Company-level read

Ticker impact

$PHATNeutralMedium confidence
Context

Phathom Pharmaceuticals disclosed that VP of Finance Robert Breedlove will resign effective December 4, 2026, with no replacement named.

Expected impact

Likely modest, two-sided reaction as traders weigh governance continuity risk versus the lack of stated operational problems.

Evidence & confidence

The article is a first-report executive resignation via an 8-K, but it lacks specifics on financial impact, timing beyond the effective date, or a named successor.

Market effects

Limited spillover to biotech finance leadership norms; no product or trial read-through provided.

No clear regional market linkage from the disclosed resignation alone.

Primarily company-specific governance and reporting continuity signal.

Counterpoint

The resignation is explicitly stated as not due to disagreement, and no replacement details may indicate a planned transition rather than distress.

Key entities

  • Phathom Pharmaceuticals, Inc.

    Subject of the 8-K executive resignation announcement.

  • Robert Breedlove

    Vice President of Finance and principal accounting officer resigning effective Dec. 4, 2026.

Related articles

$PHATMed

H.C. Wainwright reiterates Buy on Phathom stock, $26 target

H.C. Wainwright reiterated a Buy rating and $26 price target for Phathom Pharmaceuticals (PHAT), citing strong revenue growth and pipeline progress. The stock is up 8.36% weekly but down 62.5% year-to-date. Phathom reported Q3 2026 EPS of $0.04, beating estimates, but revenue missed slightly. The company is focused on VOQUEZNA's commercial execution and regulatory exclusivity.

$PHATMed

Phathom Pharmaceuticals Inc (PHAT) (Q3 2026) Earnings Call Highlights: Second

Phathom Pharmaceuticals (PHAT) reported stable commercial insurance coverage and no expected changes from a second PCAB entrant. Gross margin decline was due to a one-time manufacturing charge. Q4 revenue growth may reach the upper half of guidance due to momentum and Medicare Part D coverage. Phase 2 EOE trial data will be reported this quarter, with pediatric exclusivity discussions in 2027. 2027 revenue is expected to grow faster than operating expenses, driving positive cash flow.

$PHATMed

What Phathom Pharmaceuticals (PHAT) Said on Its Q3 Earnings Call

Phathom Pharmaceuticals (PHAT) reported Q3 gross profit margin of 78%, below guidance due to one-time charges. The company expects full-year 2026 gross-to-net discount toward the lower end of its 55%-59% range and maintains cash operating expense guidance of $235M-$245M. Phathom anticipates top-line data from its Phase II pHalcon-EoE study in Q4 and plans to discuss a Phase III program with the FDA in 2027 if results support further development.

$PHATMed

Phathom Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary

Phathom Pharmaceuticals reported Q3 2026 revenue of $84.7M, up 71% YoY, and maintained positive cash flow. The company launched 'Access First' to improve prescription adoption and introduced a $0 copay program. It reiterated FY2026 revenue guidance of $310M-$325M and expects durable positive cash flow in 2027. Phase II data for EoE is anticipated in Q4 2026.

$PHATMed

Phathom (PHAT) Q3 2026 Earnings Call Transcript

Phathom (PHAT) reported Q3 2026 net revenues of $84.7M, operating profit of $5.8M, and cash from operations of $2.1M. The company highlighted strong prescription growth for VOQUEZNA, with 2M+ prescriptions filled since launch. Phathom reiterated its full-year revenue guidance of $310M-$325M and discussed legal action by BDR Pharmaceuticals challenging VOQUEZNA's exclusivity period.